

University of Groningen

## Exploring anti-fibrotic drugs

Luangmonkong, Theerut

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

### *Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*  
2017

[Link to publication in University of Groningen/UMCG research database](#)

### *Citation for published version (APA):*

Luangmonkong, T. (2017). *Exploring anti-fibrotic drugs: Focusing on an ex vivo model of fibrosis*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.

### **Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### **Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

## **Paranymphs**

Dorenda Oosterhuis

Su Suriguga

The research presented in this PhD thesis was performed at the Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, the Netherlands.

Cover and layout: Theerut Luangmonkong

Printed: Proefschriftmaken

ISBN (printed version): 978-94-034-0187-4

ISBN (electronic version): 978-94-034-0186-7

©Theerut Luangmonkong, 2017

All right reserved. Copyright of the published articles is with the corresponding journal or otherwise with the author. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing from author or the copyright-owning journal.



university of  
 groningen

# Exploring anti-fibrotic drugs

Focusing on an *ex vivo* model of fibrosis

## PhD thesis

to obtain the degree of PhD at the  
 University of Groningen  
 on the authority of the  
 Rector Magnificus Prof. E. Sterken  
 and in accordance with  
 the decision by the College of Deans.

This thesis will be defended in public on

Monday 27 November 2017 at 09.00 hours

by

**Theerut Luangmonkong**

born on 9 October 1982  
 in Bangkok, Thailand

## **Supervisors**

Prof. dr. P. Olinga

Prof. dr. C. Suthisisang

## **Co-supervisor**

Dr. H.A.M. Mutsaers

## **Assessment Committee**

Prof. dr. R.A. Bank

Prof. dr. K.N. Faber

Prof. dr. M. Kruithof - de Julio

Prof. dr. K. Sripha

# Contents

Introduction, scope and aims	7
Part A: Exploring anti-fibrotic drugs for the treatment of liver fibrosis	9
Chapter A1 Evaluating the anti-fibrotic potency of galunisertib in a human <i>ex vivo</i> model of liver fibrosis	11
Chapter A2 <i>In vitro</i> and <i>ex vivo</i> anti-fibrotic effects of LY2109761, a small molecule inhibitor against TGF- $\beta$	33
Chapter A3 Human precision-cut liver slices as a model to test anti-fibrotic drugs in the early onset of liver fibrosis	49
Chapter A4 Targeting oxidative stress for the treatment of liver fibrosis	69
Part B: Development of novel disease models	89
Chapter B1 Pathophysiological model of non-alcoholic fatty liver disease using precision-cut liver slices	91
Chapter B2 Precision-cut human kidney slices as a model to elucidate the process of renal fibrosis	103
General discussion and perspectives	117
Summary – Samenvatting – <b>সম্বন্ধ</b>	129
Acknowledgements	135
Curriculum vitae	139

## Lists of supplementary box

Box I	Transforming growth factors	10
Box II	Small molecule drugs	32
Box III	Free radicals	68
Box IV	Metabolic syndrome	90